Prime Medicine, Inc. PRME
Nov 3, 2026, 3:39 PM EST
- YTD
- +28.67%
- 1 year
- -2.08%
- Market cap
- 809.85M
- Revenue (ttm)
- 4.96M
- EPS (ttm)
- -1.07
- Shares out
- 178.27M
- Forward P/E
- -3.96
- YTD return
- +28.67%
- 1-year return
- -2.08%
- Volume
- 3.15M
- Avg volume
- 4.05M
- Open
- 4.50
- Previous close
- 4.44
- Day's range
- 4.44 – 4.89
- 52-week range
- 2.67 – 5.91
- Beta
- 2.67
- Analysts
- Buy
- Price target
- 6.50 (+45.6%)
YTD +0.95 (+26.91%)
Key statistics
- Enterprise value
- 828.19M
- PEG ratio
- 0.00
- Price / sales
- 200.88
- Price / book
- 12.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -103.37M
- Total cash
- 101.75M
- Total debt
- 119.74M
- Return on equity
- -154.81%
- Short % of float
- 18.46%
- 50-day average
- 4.61
- 200-day average
- 2.96
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 6.50
- Target (high)
- 10.00
- Strong buy1
- Buy6
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.24724.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2025 | Chardan Capital | main | Buy | Buy |
| May 27, 2025 | Citigroup | down | Buy | Neutral |
| May 20, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
| May 20, 2025 | JP Morgan | down | Overweight | Neutral |
| May 20, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| May 19, 2025 | Chardan Capital | main | Buy | Buy |
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- primemedicine.com
News
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? 
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units 
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why 
Leading Indicators For The October Breakout Cycle 
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday 
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease 
Prime Medicine Gets FDA Green Light for Gene Editing Study 
Prime Medicine Gets FDA Green Light for Gene Editing Study
Your note
Sign in to keep a note on PRME — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS X LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 31, 2025 | 0 |
| BRUDNICK RICHARD | Officer | Purchase | May 19, 2025 | 20,000 |
| GOTTESDIENER KEITH MICHAEL | Chief Executive Officer | Stock Gift | Oct 7, 2024 | 0 |
| GV 2021 GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 31, 2025 | 0 |
| LEE ANN LOUISE | Officer | Purchase | May 20, 2025 | 100,000 |
| LIU DAVID R | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2025 | 20,240,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alphabet Inc. | 11.19% | 15,062,498 | 84.20M | Jun 29, 2025 |
| T. Rowe Price Investment Management, Inc. | 4.82% | 6,484,787 | 36.25M | Jun 29, 2025 |
| Blackrock Inc. | 3.33% | 4,485,828 | 25.08M | Jun 29, 2025 |
| FMR, LLC | 2.78% | 3,744,427 | 20.93M | Jun 29, 2025 |
| Vanguard Group Inc | 2.70% | 3,627,510 | 20.28M | Jun 29, 2025 |
| ARK Investment Management, LLC | 1.73% | 2,322,669 | 12.98M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.55% | 4,771,008 | 26.67M | Sep 29, 2025 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.65% | 3,569,787 | 19.96M | Jun 29, 2025 |
| -Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 1.58% | 2,124,252 | 11.87M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.56% | 2,095,110 | 11.71M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.06% | 1,429,992 | 7.99M | Aug 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.71% | 952,950 | 5.33M | Jun 29, 2025 |